Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

AbCellera Biologics (ABCL) Change in Accured Expenses (2024 - 2025)

AbCellera Biologics' Change in Accured Expenses history spans 2 years, with the latest figure at $5.7 million for Q4 2025.

For the quarter ending Q4 2025, Change in Accured Expenses fell 13.21% year-over-year to $5.7 million, compared with a TTM value of $3.5 million through Dec 2025, down 67.49%, and an annual FY2025 reading of $3.5 million, down 67.49% over the prior year.
Change in Accured Expenses for Q4 2025 was $5.7 million at AbCellera Biologics, up from $5.1 million in the prior quarter.
The five-year high for Change in Accured Expenses was $6.6 million in Q4 2024, with the low at -$4.9 million in Q1 2024.